PHARMAQ starts fish vaccination in Vietnam (2011-10-18)
The vaccine ALPHA JECT® Panga 1 received an observation license from the Department of Animal Health, under Ministry of Agriculture and Rural Development (MARD) in Vietnam, on October 12th 2011. The term observation means that the vaccinated fish will be followed closely by the authorities and PHARMAQ. "This is the first ever fish vaccine commercially available in Vietnam and represents a breakthrough to both the Vietnamese seafood industry and to PHARMAQ", says Kjersti Gravningen, General Director PHARMAQ Vietnam Ltd.
ALPHA JECT® Panga 1 is a vaccine administered by injection that provides protection against the bacteria Edwardsiella ictaluri causing disease in pangasius. PHARMAQ Vietnam is entering into a new phase with the exiting challenge of establishing the best practice for fish vaccination in Vietnam. Activities will include vaccination training and close collaboration with the farmers during and after vaccination. "Our team is prepared and ready for these challenges. The implementation of vaccination will make difference for the farmers in Vietnam." Kjersti Gravningen enthusiastically concludes.
"By the introduction of ALPHA JECT® Panga 1 we have reached a great milestone in the history of PHARMAQ and taken another step to strengthen our presence in the global fish health market. Our activities in Vietnam are an essential part of our strategy in exploring the potential of the Asian aquaculture industry", says Morten Nordstad, CEO in PHARMAQ.
For further information, please contact:
Kjersti Gravningen General Director PHARMAQ Vietnam Ltd.
E -mail kjersti.gravningen@pharmaq.no
Office +84 839 301 991
Mobile +84 909 558 678, +47 909 75 017
______________________________________________________________
PHARMAQ AS is the world's leading pharmaceutical company supplying the aquaculture industry. The company provides environmentally sound, safe and efficacious health products to the global aquaculture industry through targeted research and the commitment of dedicated people. The vaccines are manufactured in a state-of-the-art production facility in Overhalla in Nord-Trøndelag, Norway. Administration and research and development activities are based in Oslo. With subsidiaries in Chile, United Kingdom, Vietnam and Turkey, PHARMAQ has more than 140 employees. The company's products are marketed in Europe, North and South America, and Asia. PHARMAQ's majority shareholders are Orkla and the investment company Kverva. The management and employees hold a considerable stake in the company. For further information, please visit our website: www.pharmaq.no
